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Summary 
Differentiation factor (D factor), also called leukemia inhibitory factor (LIF), is a glycoprotein 
that has been increasingly recognized to possess a wide range of physiological activities. We examined 
the possibility that the administration olD factor may confer beneficial effects and enhance host 
resistance against lethal endotoxemia. A single intravenous dose of recombinant human D factor 
completely  protected  C57/B16  mice  from  the  lethal  effect  of  Escherickia  coli  endotoxin 
(lipopolysaccharide  [LPS]).  The  protective  effects were dose dependent  and  observed when 
administered 2-24 h before LPS. Previous work has shown that interleukin  1 (Ibl) and tumor 
necrosis factor (TNF) also protect against a subsequent LPS challenge in a dose-dependent manner. 
When human D  factor was combined with sub-protective doses of IL-I~ or TNF-ol, there was 
dramatic  synergistic protection  against  a subsequent lethal LPS challenge. 
D 
ifferentiation factor (D factor), also known as leukemia 
inhibitory factor (LIF), is a pluripotent  glycoprotein 
with important regulatory physiological activities which in- 
clude the ability to induce maturation and decrease clonage- 
nicity of murine and human leukemia cells (1, 2); direct pheno- 
type expression  in  neuronal  tissue  (3);  induce  changes  in 
calcium metabolism (1, 4); and promote acute phase protein 
synthesis in hepatocytes (5). In vivo, D  factor has a remark- 
able variety of other potent  activities (1,  6).  A  role for D 
factor in the host response against bacterial infection is sug- 
gested by the finding that serum levels of D factor are detect- 
able in mice after the administration  of endotoxin  (7). 
IL-1 and TNF are similarly pluripotent,  highly conserved 
peptide cytokines which,  when administered before an in- 
sult, will confer in vivo protection against the lethal effects 
of radiation (8), endotoxin or Gram-negative sepsis (9, 10), 
ischemia/reperfusion injury (11), and oxygen toxicity (12, 13). 
Because TNF and ILol require a pretreatment  interval,  this 
suggests that the cytokines may confer protective effects in- 
directly. It is interesting that TNF and IL-1 have been shown 
to induce the synthesis olD factor in vitro (14). The current 
studies were performed to investigate the possibility that D 
factor may also have an important protective role against the 
lethality of endotoxin, and to investigate the effect olD factor 
in  modulating  the protective properties  of IL-1 and TNF. 
Materials  and Methods 
Animals.  Female  C57/B16 mice weighing 19-21 g were housed 
five to six per cage and kept in a controlled environment.  All ex- 
periments  were conducted in compliance with the Animal Care 
and Use Committee of the National  Institutes  of Health. 
Reagents.  Human ffNF-c~ and Ibl/8 were produced from Esch- 
erichia coli, and had an endotoxin content of<2 Eu/mg (15). Human 
and murine rD factor were produced as previously described, and 
had  an endotoxin  content of <2 Eu/mg (16). All reagents were 
brought to final concentration  in PBS with 0.5% fatty acid-poor 
endotoxin-free BSA (Calbiochem-Behring  Corp.,  La Jolla,  CA), 
and kept at 2-8~  until administered. Control mice received inert 
protein carrier solution  (saline). E. coli endotoxin  (LPS, serotype 
0127:B8) was purchased from Sigma Chemical Co. (St. Louis, MO), 
and reconstituted  in saline to a final concentration  of 4 mg/ml. 
Survival Extx,'riments.  All survival experiments followed the same 
general format. In initial experiments animals (n =  10-12/group) 
were injected with increasing concentrations  of D factor by tail 
vein (0.4 ml/mouse),  followed 24 h later by either 35 or 40 mg/kg 
E. coli LPS intraperitoneally. In the kinetics studies, D factor injec- 
tions were staggered at various intervals before LPS. Control animals 
received an equal volume of saline. In the synergy experiments, 
all animals received two tail vein injections of the pertinent reagents 
or an equal volume of saline. Survival was assessed at frequent in- 
tervals for 72 h, and then daily for 6 d. In this model, LPS lethality 
occurs from 24-72 h, at which time surviving animals are recovering 
and appear stable (9). 
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vival at 72 h were determined using Fisher's exact test. Other 
significant  differences  in survival  between groups were determined 
by the Breslow modification of the Kruskal-Wallis  test. In synergy 
experiments, the logarithms of the survival times were assumed 
to be the sums of the effects of D factor, II.-1, or TNF, and an 
interaction term with a logistic error distribution. The likelihood 
ratio test was used to assess the significance  of the interaction after 
adjusting for the two main effects. 
Results and Discussion 
To test the protective effects of human rD factor against 
LPS, mice received an intravenous injection of increasing con- 
centrations of the protein 24 h before LPS (Table 1, A). The 
protective effects of D  factor were dose dependent and 500 
/zg/kg completely protected mice from a 95%  lethal dose 
(LDgs) or greater of LPS. In initial experiments, comparable 
improvements in survival  were also observed  with murine 
D factor (data not shown), and subsequent experiments were 
performed with the human homologue. The similar protec- 
tion was not unexpected in light of the fact that the human 
and murine proteins share 78% amino acid homology and 
have equally high affinity for specific cellular  receptors  on 
murine cells (2, 17). The protective effects of D factor were 
observed  at doses up to 1,500 #g/kg, and did not produce 
any observable toxicity. The protein used in these experiments 
was expressed in CHO cells and had an endotoxin content 
of <2 Eu/mg, minimizing the possibility that any toxic or 
protective effects were produced by endotoxin contamination. 
Protection was produced rapidly and observed with a pretreat- 
ment interval of 2 h or greater (Table 1). After the injection 
of LPS, mice in both groups initially appeared ill with hud- 
died posture and piloerection, which suggested that pretreat- 
ment with D  factor did not simply inactivate the LPS. 
Our laboratory has previously reported that a single intra- 
venous dose of I1.-1 will protect mice against a subsequent 
lethal challenge with endotoxin (9). The profile of protec- 
tive effects is similar to that of D  factor,  requiring only a 
2 h pretreatment interval, and having a broad range of non- 
toxic therapeutic doses. Single intravenous sub-protective doses 
of D  factor and IL-1, when given in combination, showed 
synergistic protection against LPS lethality (Fig.  1). 
Pretreatment with TNF has also been shown to protect 
against lethal endotoxemia or bacterial sepsis (10). When a 
single intravenous dose of  TNF-ot, 25/~g/kg, was administered 
with D  factor,  10/xg/kg, there was also synergistic protec- 
tion against a subsequent lethal LPS challenge (Fig. 2). How- 
ever, complete protection against LPS with a combination 
of D factor and TNF was not observed because dose escala- 
tion of TNF alone produced a significant survival advantage 
against LPS lethality. The combination of D factor with ei- 
ther Ibl or TNF did not appear toxic under these experimental 
conditions, but clearly synergized the therapeutic effects. In 
contrast, low doses of TNF  and II,-1 have been shown to 
result in synergistic lethality (18). It appears  that IL-1 and 
D  factor are ideally suited for use in combination because 
of their minimal toxicity in association with the synergistic 
effects. 
The mechanism by which IL-1 or TNF exert their beneficial 
effects is not understood, but may be related to their ability 
to selectively induce gene expression of manganous superoxide 
dismutase (MnSOD) (19), an inducible mitochondrial metal- 
loenzyme that protects cells against injury from reactive ox- 
ygen species (20). D factor alone does not induce this antiox- 
Table  1.  D  Factor Protection against E.  Coli  LPS Lethality  in Female C57/B16 Mice 
Time of  Intraperitoneal  72 h 
Exp.  Group  Dose  Rx  LPS  survival  P2 
h 
A  D  factor  1  -  24  40  0/10  - 
D  factor  10  -  24  40  3/12  - 
D  factor  100  -  24  40  4/10  - 
D  factor  500  -  24  40  10/10  <0.001" 
Saline  -  - 24  40  2/13  - 
B  D  factor  500  - 24  35  9/9  0.02* 
D  factor  500  - 6  35  11/11  0.01" 
Saline  -  - 6  35  8/15  - 
C  D factor  500  - 2  40  11/12  <0.001" 
Saline  -  - 2  40  0/12  - 
D  D factor  500  0  35  6/15  - 
Saline  -  0  35  7/15 
* Versus saline 
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Figure 1.  Synergistic protection olD fictor and 1I--1 against LPS lethality. 
Mice were treated with increasing doses of IL-1 or D  factor alone,  or in 
combination 24 h before LPS, 40 mg/kg, intraperitoneally  as described. 
Control mice received an equal volume of saline. (21) IIr  or D  factor did 
not confer protection  against LPS compared with controls. The combina- 
tion of cytokines  resulted in a significantly  improved  survival compared 
with any other  treatment  (p =  0.025).  (B) Dose  escalation  of  both cytokines 
resulted in synergistic protection against LPS (p =  0.0014).  In this experi- 
ment, control lethality was 7:12 and not significantly different than Ibl 
or D  factor alone. (C) D  factor, 100 #g/kg, conferred significant protec- 
tion against controls (p  =  0.002).  In combination with a nonprotective 
dose of IL-1, there was significantly improved survival against LPS com- 
pared with D  factor or IL-1 alone (p  =  0.01). 
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Synergistic protection of D  factor and TNF  against LPS 
lethality.  TNF or D  factor were given 24 h before LPS as described. Sur- 
vival with either TNF or D  factor alone was not different than controls. 
Combination treatment resulted in significantly  improved survival (p  = 
0.04).  Horizontal axis represents time in days. 
idant enzyme, but does act synergistically with TNF and 11:1 
on the induction of MnSOD in M1 cells (G. Wong, unpub- 
lished  data).  D  factor  is  synonymous  with  hepatocyte 
stimulating factor III (2, 5, 7) and the modulation of acute 
phase protein synthesis before or during endotoxemia may 
also be a contributing beneficial effect. Recently, the binding, 
internalization, and partial degradation of endotoxin by scav- 
enger receptors on macrophages has been implicated as a mech- 
anism by which circulating endotoxin is cleared and detoxified 
in animals (21). Because macrophages and monocytes appear 
to be the primary target cell responsible for binding of D 
factor (22, 23), the function of these cell types may be al- 
tered after exposure to D  factor and result in an accelerated 
rate of endotoxin clearance or augmented production of TNF 
or I1:1 in response to LPS. 
In conclusion, these experiments demonstrate that D factor 
has important physiological effects that may enhance the host 
defense against a variety of acute disease processes as demon- 
strated in this model of endotoxin shock. The studies ex- 
pand the known in vivo properties of  exogenously administered 
D  factor and demonstrate therapeutic synergism with I1:1 
or TNF. Recent work has also shown that D factor has syn- 
ergistic activity with TNF against radiation lethality in mice 
(24).  The synergism of D factor with I1:1 or TNF suggests 
that D factor is unlikely to be the sole mediator of the pro- 
tective activity of II:1  and TNF.  The application of these 
cytokines in combination with D  factor may be extremely 
useful against a variety of disease processes  ameliorated by 
I1:1  or TNF  treatment. 
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